StageBio Acquires TPL Path Labs

October 21, 2020

StageBio, a portfolio company of Ampersand Capital Partners, has acquired TPL Path Labs of Freiburg, Germany, expanding its GLP/GCLP-compliant preclinical and clinical histopathology and molecular pathology capabilities in Europe. The deal increases StageBio's global scale and ability to serve multinational biopharma, medical device and academic researchers by adding a German laboratory facility and staff.

Buyers
StageBio, Ampersand Capital Partners
Targets
TPL Path Labs (TPL Path Labs GmbH)
Platforms
StageBio
Location
Baden-Württemberg, Germany
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.